Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 16/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29113 | 0.89 | CCR9 (1.00) | CCR9LMNAHTTBDKRB1 | |
| SCHEMBL13146479 | 0.88 | CCR9 (0.84) | CCR9LMNAHTTBDKRB1 | |
| SCHEMBL12359492 | 0.86 | CCR9 (0.84) | CCR9LMNAHTTBDKRB1 | |
| SCHEMBL344527 | 0.85 | CCR9 (0.88) | CCR9LMNAHTTBDKRB1 | |
| SCHEMBL27321 | 0.85 | CCR9 (0.88) | CCR9LMNAHTTBDKRB1 | |
| SCHEMBL342801 | 0.85 | CCR9 (0.88) | CCR9LMNAHTTBDKRB1 | |
| SCHEMBL26659 | 0.85 | CCR9 (0.82) | CCR9LMNAHTTBDKRB1 | |
| SCHEMBL343529 | 0.84 | CCR9 (0.86) | CCR9LMNAHTTBDKRB1 | |
| SCHEMBL344930 | 0.83 | CCR9 (0.76) | CCR9LMNAHTTBDKRB1 | |
| SCHEMBL14574509 | 0.83 | CCR9 (0.82) | CCR9LMNAHTTBDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402310-A1 | CCR9 inhibitors and methods of use thereof | Millennium Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | claimed |
| EP-2399903-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | claimed |
| WO-2008008374-A2 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMECEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMECEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| EP-1507756-B1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-9035096-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9035096-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140107160-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107160-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8569543-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20080103180-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103180-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008008374-A2 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-7282502-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282502-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-7238717-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238717-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070066823-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070066823-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107160-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | CCR9 1/4885LMNA 3548/4885HTT 4358/4885 |
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | CCR9 1/4885LMNA 3548/4885HTT 4358/4885 |
| US-20070066823-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | CCR9 1/4885LMNA 3548/4885HTT 4358/4885 |
| US-20080103180-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | CCR9 1/4885LMNA 3548/4885HTT 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.